Dietary Impact on Esophageal & Stomach Cancer & Its Possible Management

Abstract

Cancer is an aberrant cell development that has a propensity to multiply uncontrollably. There are 32.6 million people worldwide who have cancer of some kind, and 456 000 of them have esophageal cancer. Approximately 80% of instances were found in less developed parts of the world. Gender discrepancy was shown by an incidence ratio of 2.4:1 in males and women. This study revealed that dietary acrylamide consumption was not linked to an elevated incidence of esophageal, gastric, or colorectal cancer. One of the fundamental meals in the human diet, cereals are primarily ingested as refined grains. The risk of various gastrointestinal cancers is inversely correlated with WG ingestion, most consistently with the risk of colorectal tumor. The only available treatment for regionalized gastric and esophageal cancer is surgical resection (R0). Due to the short life expectancy (20–50% at 5 years) following surgery alone, efforts must be made to improve health satisfaction with perioperative chemotherapy or postoperative (adjuvant) chemoradiotherapy. Approved Drugs for gastric cancer Cyramza (Ramucirumab), Docetaxel, Doxorubicin Hydrochloride, Enhertu (Fam-Trastuzumab Deruxtecan-nxki), 5-FU (Fluorouracil Injection), Fam-Trastuzumab Deruxtecan-nxki, Fluorouracil Injection. Approved Drugs for esophageal cancer Keytruda (Pembrolizumab), Nivolumab, Opdivo (Nivolumab), Pembrolizumab. The mortality rates for individuals with stomach cancer have improved as a result of advancements and the availability of numerous additional reference chemotherapy regimens.